BofA raised the firm’s price target on Jazz Pharmaceuticals to $217 from $204 and keeps a Buy rating on the shares following what the firm calls “a solid 2Q print.” Exiting Q2, the firm makes “modest changes” to its sales forecast, reflecting slower 2023 Xyrem erosion and better Rylaze performance, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JAZZ:
- Jazz Pharmaceuticals sees FY23 adjusted EPS $18.15-$19.00, consensus $17.48
- Jazz Pharmaceuticals resumed share repurchases in Q2
- Jazz Pharmaceuticals reports Q2 adjusted EPS $4.51, consensus $4.42
- Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?